Agile Therapeutics traded at $0.57 this Friday August 12th, decreasing $0.08 or 11.93 percent since the previous trading session. Looking back, over the last four weeks, Agile Therapeutics lost 11.95 percent. Over the last 12 months, its price fell by 45.15 percent. Looking ahead, we forecast Agile Therapeutics to be priced at 0.55 by the end of this quarter and at 0.50 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Adma Biologics 2.37 0.14 6.28% 59.06%
Agile Therapeutics 0.57 -0.08 -11.93% -45.15%
Bayer 54.02 -0.13 -0.24% 13.12%
BioMarin Pharmaceutical 95.07 0 0% 26.71%
Jazz Pharmaceuticals 157.08 2.83 1.83% 10.50%
J&J 165.30 -1.84 -1.10% -6.21%
Merck & Co 91.02 2.09 2.35% 18.64%
Pacira 57.56 1.30 2.31% -1.30%
Pfizer 50.11 1.82 3.77% 3.36%
Cassava Sciences Inc. 20.42 0.57 2.87% -83.34%
Teva Pharmaceutical Industries 11.21 0.12 1.08% 14.04%
TherapeuticsMD 9.21 0.16 1.77% 969.44%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%

Agile Therapeutics
Agile Therapeutics, Inc. is a women’s healthcare company. The Company’s approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla uses its transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability, which may help support compliance. Its product pipeline consists of two types of product candidates: Twirla line extensions and other transdermal contraceptive product candidates. These potential product candidates are designed to address market needs of additional non-daily contraceptive options. Its Twirla line extensions include AG200-15 Extended Regimen (ER), AG200-15 SmP, AG200-15 ER SmP, and AG890, a P-only contraceptive patch.